FBLG

Fibrobiologics Inc. (FBLG) | Rumor.io

Fibrobiologics

FBLG

Attention (50-day avg)0%

Attention rank (50-day avg)#1,565

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.16

Market capitalization9.5M

Earnings per share-5.1

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-18.6M

Social

What share of all stock conversation is about FBLG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 1

FibroBiologics, Inc. (FBLG) has been issued a U.S. patent for the treatment of degenerative disc disease using fibroblast conditioned media.
The stock has been experiencing high trading volume, with over 1/8 of the total stock being traded on a single day, and the price has been rising significantly.
Analysts and investors are optimistic about the stock's potential, with some predicting a move to the $3 to $3.4 zone and a possible price of $10.

Generated by AI

Sentiment

Of the messages about FBLG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	88.09% -4.18
Bearish	—	—	0% 0	11.91% +4.18

Bullish· Jul 13

FBLG has shown significant momentum with a +6.469221835075491% increase, indicating a strong upward trend.
The company's stock price is experiencing a "buy frenzy" with investors actively purchasing shares, contributing to the stock's rapid rise.
FBLG's price surge is characterized as "ridiculous momentum" and "insane," with some investors even describing it as "printing money like crazy" and "printing money nonstop."

Bearish· Mar 31

$FBLG's current stock price is significantly lower than the expected offering price of around $4 per share.
The company is subject to Nasdaq listing rules, which require it to keep its stock price above $1, making an offering at a lower price unlikely.
The stock's price drop is attributed to market participants' misinterpretation of news, with some believing it's an easy target for shorting.

Generated by AI

Topics

Of the messages about FBLG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	30.77%	62.18%
Technical Analysis	—	—	69.23%	12.41%
Macro	—	—	0%	12.06%
Analysts	—	—	0%	10.77%
Controversies	—	—	0%	1.87%
Earnings	—	—	0%	0.7%

Apr 1

FibroBiologics ($FBLG) has priced a $3 million public offering of 2.3 million shares and warrants at $1.32 per unit, introducing dilution risk and expected volatility.
The company's clinical-stage biotech with extensive IP is seeking capital, and traders should expect significant options flow and monitor key support levels.
As a result of the offering, traders should prioritize risk management and scale in gradually, considering the potential for a momentum shift and volatility in the share price.

Generated by AI

Community

Of the messages about FBLG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	35.09%	44.48%
Newcomers	—	100%	64.91%	55.52%

Apr 1

The public offering of $FBLG priced at $1.32 per share is expected to generate significant options flow and may lead to heightened volatility.
The offering introduces dilution risk, and traders should manage position size accordingly to mitigate this risk.
Key support levels will be crucial to watch after the public offering, and monitoring volume closely is essential to determine the subsequent move.

Generated by AI

ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 26, at 7:00 p.

4d agoYahoo Finance

FibroBiologics CSO invests $500,000 in private placement By Investing.com

12d agoInvesting.com

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

12d agoMorningstar

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' strategy to develop off-the-shelf fibroblast-based cell therapies for chronic diseases and regenerative medicine. The Company is advancing a platform designed to harness the regenerative and immune-modulating properties of fibroblasts across multiple indications, including chronic wound care, psoriasis, multiple sclerosis, degenerative disc disease, and thymus regeneration.

22d agoYahoo Finance

Also Discussed

Investors talking about FBLG also mention

#	Name	Attention
1	Aspire Biopharma Holdings, Inc.ASBP	0%new
2	Agape Atp CorpATPC	0%0
3	OneMedNet Corp. Class A Common StockONMD	0.02%+0.02
4	Allied Gaming & Entertainment Inc.AGAE	0%0
5	TuHURA Biosciences, Inc.HURA	0%0
6	Republic Bancorp, Inc. Class A Common StockRBCAA	0%0
7	VIVK - Vivakor, Inc.	——
8	Tharimmune Inc.THAR	0%new
9	Kyverna Therapeutics, Inc.KYTX	0%0
10	Captivision Inc.CAPT	0%new

Fibrobiologics Inc.

Healthcare
Biotechnology

Fibrobiologics Inc. is a cutting-edge biotechnology company involved in the field of regenerative medicine. This company's primary focus is on the development of fibroblast-based technologies and therapies aimed at repairing and regenerating damaged tissues. Fibrobiologics uses fibroblast cells, which are critical for tissue maintenance and wound healing, to create innovative treatments for a variety of conditions, including chronic wounds, degenerative diseases, and age-related conditions. The firm heavily engages in research and development, working to harness the natural capabilities of fibroblasts in addressing unmet medical needs. The role of Fibrobiologics Inc. in the financial market is significant due to its potential impact on the healthcare sector, as advancements in regenerative medicine could lead to major breakthroughs in patient care and treatment efficacy. Within the broader biotechnology industry, Fibrobiologics plays a crucial role, contributing to the ongoing evolution of next-generation therapies that are likely to enhance the quality of life for many patients.

Website

Location

455 East Medical Center Boulevard

Houston, TX, 77598

United States

Social

What share of all stock conversation is about FBLG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 1

FibroBiologics, Inc. (FBLG) has been issued a U.S. patent for the treatment of degenerative disc disease using fibroblast conditioned media.
The stock has been experiencing high trading volume, with over 1/8 of the total stock being traded on a single day, and the price has been rising significantly.
Analysts and investors are optimistic about the stock's potential, with some predicting a move to the $3 to $3.4 zone and a possible price of $10.

Generated by AI

Sentiment

Of the messages about FBLG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	88.09% -4.18
Bearish	—	—	0% 0	11.91% +4.18

Bullish· Jul 13

FBLG has shown significant momentum with a +6.469221835075491% increase, indicating a strong upward trend.
The company's stock price is experiencing a "buy frenzy" with investors actively purchasing shares, contributing to the stock's rapid rise.
FBLG's price surge is characterized as "ridiculous momentum" and "insane," with some investors even describing it as "printing money like crazy" and "printing money nonstop."

Bearish· Mar 31

$FBLG's current stock price is significantly lower than the expected offering price of around $4 per share.
The company is subject to Nasdaq listing rules, which require it to keep its stock price above $1, making an offering at a lower price unlikely.
The stock's price drop is attributed to market participants' misinterpretation of news, with some believing it's an easy target for shorting.

Generated by AI

Topics

Of the messages about FBLG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	30.77%	62.18%
Technical Analysis	—	—	69.23%	12.41%
Macro	—	—	0%	12.06%
Analysts	—	—	0%	10.77%
Controversies	—	—	0%	1.87%
Earnings	—	—	0%	0.7%

Apr 1

FibroBiologics ($FBLG) has priced a $3 million public offering of 2.3 million shares and warrants at $1.32 per unit, introducing dilution risk and expected volatility.
The company's clinical-stage biotech with extensive IP is seeking capital, and traders should expect significant options flow and monitor key support levels.
As a result of the offering, traders should prioritize risk management and scale in gradually, considering the potential for a momentum shift and volatility in the share price.

Generated by AI

Community

Of the messages about FBLG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	35.09%	44.48%
Newcomers	—	100%	64.91%	55.52%

Apr 1

The public offering of $FBLG priced at $1.32 per share is expected to generate significant options flow and may lead to heightened volatility.
The offering introduces dilution risk, and traders should manage position size accordingly to mitigate this risk.
Key support levels will be crucial to watch after the public offering, and monitoring volume closely is essential to determine the subsequent move.

Generated by AI

Fibrobiologics

Social

Sep 1

Sentiment

Bullish· Jul 13

Bearish· Mar 31

Topics

Apr 1

Community

Apr 1

News

FibroBiologics receives European patent for fibroblast therapy

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

FibroBiologics CSO invests $500,000 in private placement By Investing.com

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

Also Discussed

Fibrobiologics Inc.

Company Information

Location

News

FibroBiologics receives European patent for fibroblast therapy

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

FibroBiologics CSO invests $500,000 in private placement By Investing.com

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

Also Discussed

Social

Sep 1

Sentiment

Bullish· Jul 13

Bearish· Mar 31

Topics

Apr 1

Community

Apr 1